Actylis expands portfolio and capabilities with Pharm-Rx acquisition
Advanced technology specialty ingredients supplier, Actylis, reveals it has acquired Pharm-Rx, a supplier of specialty ingredients for the pharmaceutical and vitamin, mineral and supplement (VMS) industries.
Actylis says the acquisition boosts the company’s ability to deliver customer value, increases its solutions range, bolsters its supplier partnerships and strengthens its service offerings and innovative portfolio.
Actylis points out that Pharm-Rx’s expertise will drive its growth in nutrition and over-the-counter (OTC) pharmaceutical clients. To help aid in the transition, the current president and head of business development at Pharm-Rx, Mark Bostel, will take on the role of president of global nutrition and OTC at Actylis and oversee both Pharm-Rx’s and Actylis’ nutrition and OTC operations.
“This acquisition is a significant milestone in our growth strategy, allowing us to offer even greater value to our customers through an expanded portfolio and enhanced capabilities and expertise,” says Scott Thomson, the CEO of Actylis. “By leveraging our combined strengths, we are poised to deliver the most innovative solutions to meet the ever-evolving needs of the markets that we serve.”
“We are excited to welcome Mark Bostel to the Actylis leadership team and work together to drive accelerated growth for our combined nutrition and OTC business in partnership with our customers.”
Market expansion
According to Actylis, Pharm-Rx is a leading provider of active ingredients for the VMS, OTC and prescription pharmaceutical sectors and is recognized for its customer-focused strategy, supplying rare specialty ingredients from top global manufacturers.
Moreover, it says the company has gained industry-leading proficiency in meeting client demands, surmounting regulatory challenges and managing the complexities of international logistics.
Pharm-Rx will maintain its brand identity within Actylis, with leadership provided by its existing management team. The financial details of the deal have not been released.
“Pharm-Rx found the ideal partner in Actylis — their strengths align with ours,” concludes Pharm-Rx’s Bostel. “It is clear that together, we can offer our suppliers broader access to clients globally while expanding our differentiated product offerings to our customer base.”
“We are most excited about the complementary nature of our businesses, positioning us to better serve our markets and unlock new opportunities.”
Nutrition Insight will continue to cover this story as it develops.
